Prostate Cancer

Inavolisib triplet wins FDA approval in PIK3CA+ breast cancer, perioperative pembrolizumab improves EFS in head and neck cancer, and more from OncLive this week.

The combination of talazoparib and enzalutamide improved overall survival in metastatic castration-resistant prostate cancer.

Apalutamide was associated with an improved 24-month overall survival rate vs enzalutamide in metastatic castration-sensitive prostate cancer.

The combination of nivolumab plus radiotherapy reduces rates of biochemical recurrence in gleason grade 5 prostate cancer.

Neeraj Agarwal, MD, FASCO; Andrew J. Armstrong, MD, MSc; and Timothy A. Yap, MBBS, PhD, FRCP, detail the latest research on PARP1-selective inhibitors in oncology.

Illuccix has been approved in Canada for the selection of patients with mCRPC eligible for treatment with PSMA1-targeted radionuclide therapy.

Bertram Yuh, MD, discusses the value of genetic testing, long-term disease management, and raising awareness during Prostate Cancer Awareness Month.

A supplemental new drug application seeking to expand the indication for darolutamide plus ADT in mHSPC has been submitted to the FDA.

Rintatolimod plus durvalumab led to stable disease at 6 months in 2 of 3 patients with late-stage pancreatic cancer treated at the first dose level.

Darolutamide plus ADT shows PFS benefit without docetaxel in metastatic hormone-sensitive prostate cancer.

Radium-223 plus enzalutamide yielded significant rPFS and OS benefits vs enzalutamide monotherapy in metastatic castration-resistant prostate cancer.

This list features a snapshot of key August FDA oncology decisions, efforts to integrate health equity into guideline development, and more.

The FDA approved companion diagnostics for olaparib plus abiraterone in metastatic castration-resistant prostate cancer.

Alicia Morgans, MD, MPH, discusses the use of ADT in combination with darolutamide or placebo in nonmetastatic castration-resistant prostate cancer.

The FDA has granted fast track designation to 64Cu-SAR-bisPSMA for PET imaging of PSMA-positive prostate cancer lesions.

Robert Dreicer, MD, discusses his presentation from the 17th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies.

Alicia Morgans, MD, MPH, discusses considerations for oncologists treating patients with nonmetastatic castration-resistant prostate cancer in the community setting.

Olaparib produced responses in high-risk, biochemically recurrent prostate cancer with HRR alterations, particularly BRCA2 alterations.

Praful K. Ravi, MB, BChir, MRCP, discusses the prognostic impact of residual cancer burden on long-term outcomes in high-risk localized prostate cancer.

Males harboring BRCA1/2 pathologic variants have a higher risk of developing select cancers but are less likely to undergo genetic testing.

Enzalutamide led to improved OS, PCS, TTS, and TTR vs abiraterone acetate in patients with metastatic castration-resistant prostate cancer.

Josep Maria Piulats Rodriguez, MD, PhD, discusses next steps for validating predictive biomarkers of efficacy to treatment with talazoparib plus enzalutamide in mCRPC.

Praful K. Ravi, MB, BChir, MRCP, discusses the use of neoadjuvant androgen receptor pathway inhibitors prior to radical prostatectomy in high-risk, localized prostate cancer.

Kara N. Maxwell, MD, PhD, discusses the risk of cancer for males carrying BRCA mutations.

Praful Ravi, MB, BChir, MRCP, discusses an analysis measuring residual cancer burden in localized prostate cancer after neoadjuvant therapy and surgery.

Atish D. Choudhury, MD, PhD, discusses the background of the A-DREAM trial in patients with metastatic hormone-sensitive prostate cancer.

Robert Dreicer, MD, discusses complexities surrounding biochemical failure post radical prostatectomy in patients with prostate cancer.

Praful K. Ravi, MB, BChir, MRCP, discusses the use of residual cancer burden to guide intensified neoadjuvant treatment in high-risk prostate cancer.

Jun Gong, MD, discusses the benefits and limitations of PARP inhibitor–based regimens in metastatic castration-resistant prostate cancer.

Alicia Morgans, MD, MPH, discusses key data from the follow-up analysis of the phase 3 ARAMIS trial in nonmetastatic castration-resistant prostate cancer.